Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder

The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on…

Read More

What Could the Election Mean for Data Interoperability?

Most Americans don’t understand how an administration’s view on healthcare data sharing interoperability could directly impact them, pointed out Arcadia CEO Michael Meucci. More requirements around data sharing could lead to better care continuity, improved outcomes and lower costs. The post What Could the Election Mean for Data Interoperability? appeared first on MedCity News.

Read More

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study. The post Going In…

Read More